CHRNA2 — Cholinergic Receptor Nicotinic Alpha 2
Introduction
CHRNA2 (Cholinergic Receptor Nicotinic Alpha 2) encodes the α2 subunit of the nicotinic acetylcholine receptor (nAChR) family. This ligand-gated ion channel subunit forms heteromeric receptors critical for fast cholinergic synaptic transmission throughout the peripheral and central nervous systems. CHRNA2 has been implicated in epilepsy, autonomic dysfunction, and potentially in neurodegenerative diseases including Alzheimer's Disease and Parkinson's Disease. This page covers the gene's structure, function, disease associations, and therapeutic implications.
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Cholinergic Receptor Nicotinic Alpha 2</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>CHRNA2</td></tr>
<tr><td><strong>Full Name</strong></td><td>Cholinergic receptor nicotinic alpha 2 subunit</td></tr>
<tr><td><strong>Chromosome</strong></td><td>8p21</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[1135](https://www.ncbi.nlm.nih.gov/gene/1135)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[104500](https://www.omim.org/entry/104500)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000120288</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P43681](https://www.uniprot.org/uniprotkb/P43681)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Epilepsy](/diseases/epilepsy), [Autonomic dysfunction](/diseases/autonomic-dysfunction), [AD](/diseases/alzheimers-disease), [PD](/diseases/parkinsons-disease)</td></tr>
</table>
</div>
Overview
Mermaid diagram (expand to render)
CHRNA2 is a member of the Cys-loop receptor superfamily, which also includes GABAₐ, glycine, and 5-HT3 receptors. The alpha2 subunit typically combines with beta2 or beta4 subunits to form functional heteromeric nAChRs. These receptors are expressed in both the central and peripheral nervous systems, where they mediate fast synaptic transmission and modulate neuronal excitability.
Key characteristics:
- Ligand-gated ion channel (ionotropic receptor)
- Permeable to Na+, K+, and Ca2+
- Activated by acetylcholine (ACh) and nicotine
- Subject to rapid desensitization
Protein Structure
Overall Architecture
The nAChR is a pentameric ligand-gated ion channel. CHRNA2 contributes to the formation of:
- Extracellular N-terminal domain: Contains the acetylcholine binding site
- Transmembrane domain: Four α-helices (M1-M4) forming the ion channel pore
- Intracellular loop: Between M3 and M4, contains phosphorylation sites
- Extracellular C-terminal domain
Acetylcholine Binding Site
The ACh binding site is located at the interface between adjacent subunits:
- Principal binding component: C-loop of the α subunit (CHRNA2)
- Complementary component: Adjacent non-α subunit (β2/β4)
Key structural features:
- Aromatic residues (Trp, Tyr, Phe) for ACh binding
- Disulfide bond at the tip of the C-loop (characteristic of Cys-loop receptors)
- Glycosylation sites for proper folding
Ion Channel Pore
The channel pore is formed by the M2 transmembrane helices:
- Ring of negatively charged residues at the extracellular entrance (selectivity filter)
- Hydrophobic gate region
- Intracellular entrance with additional regulatory sites
Receptor Subtypes
CHRNA2 forms heteromeric nAChRs with specific subunit compositions:
| Receptor | Stoichiometry | Expression | Function |
|----------|---------------|------------|----------|
| α2β2 | α2:β2 = 2:3 | CNS, autonomic ganglia | Major CNS receptor |
| α2β4 | α2:β4 = 2:3 | Autonomic ganglia, brain | Peripheral, some CNS |
| α2α5β2 | α2:α5:β2 = 1:1:3 | CNS | High Ca²⁺ permeability |
The α5 subunit inclusion (α2α5β2) significantly increases Ca²⁺ permeability, which has important implications for neuronal signaling and disease processes.
Expression Pattern
CHRNA2 demonstrates unique expression patterns:
Central Nervous System
- Hippocampus: CA1-CA3 pyramidal cells, dentate gyrus granule cells
- Cortex: Layer 2/3 interneurons
- Thalamus: Relay neurons
- Brainstem: Motor and sensory nuclei
- Cerebellum: Molecular layer interneurons
Peripheral Nervous System
- Autonomic ganglia: Sympathetic and parasympathetic neurons
- Enteric nervous system: Myenteric and submucosal plexus
Glial Expression
- Astrocytes (moderate)
- Microglia (low, inducible)
Role in Neuronal Signaling
Synaptic Transmission
CHRNA2-containing nAChRs mediate:
Fast excitatory transmission: Direct depolarization via Na⁺ influx
Presynaptic modulation: Ca²⁺-dependent neurotransmitter release
Postsynaptic excitation: Integration with other excitatory inputsCalcium Signaling
The Ca²⁺ permeability of α2β2* and especially α2α5β2 receptors enables:
- Activation of intracellular Ca²⁺ signaling cascades
- Synaptic plasticity mechanisms
- Gene transcription via Ca²⁺-dependent pathways
Neuromodulation
CHRNA2 receptors modulate:
- Dopaminergic signaling in the striatum
- GABAergic inhibition in cortical circuits
- Glutamatergic transmission
Role in Alzheimer's Disease
Cholinergic Hypothesis Connection
The cholinergic hypothesis of AD proposes that loss of cholinergic neurons contributes to cognitive decline. CHRNA2 is relevant because:
Presynaptic modulation: α2-containing receptors modulate ACh release
Attention and memory: nAChR signaling is critical for cognitive function
Neuroprotection: Nicotinic agonists may protect against Aβ toxicityAmyloid Interaction
- Aβ directly interacts with nAChRs
- Aβ binding may dysregulate α2-containing receptor function
- Nicotinic stimulation may reduce Aβ-induced toxicity
Tau Pathology
nAChR signaling intersects with tau pathology:
- PKC and CaMKII pathways modulate tau phosphorylation
- Cholinergic dysfunction may exacerbate tau pathology
Role in Parkinson's Disease
Dopaminergic Modulation
CHRNA2 receptors influence dopaminergic function:
- Nigrostriatal pathway modulation
- Mesolimbic and mesocortical circuits
- Motor control via basal ganglia circuits
Nicotine and PD
Epidemiological studies show:
- Smoking is associated with reduced PD risk
- Nicotine may protect dopaminergic neurons
- α4/α6-containing receptors (not α2) primarily mediate this effect
Autonomic Dysfunction
CHRNA2 mutations cause autonomic disorders:
- Dysautonomia in epilepsy patients
- Orthostatic hypotension
- Thermoregulatory dysfunction
Disease Associations
Epilepsy
CHRNA2 mutations cause autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE):
- Phenotype: Brief seizures during sleep
- Mechanism: Gain-of-function mutations increase channel activity
- Treatment: Carbamazepine (Na⁺ channel blocker)
Autonomic Dysfunction
CHRNA2 mutations are associated with:
- Autonomic seizures
- Central hypoventilation
- Cardiac arrhythmias
Alzheimer's Disease (Potential)
- Altered nAChR expression in AD brains
- CHRNA2 polymorphism associations with AD risk
- Therapeutic targeting of nAChRs
Parkinson's Disease (Potential)
- nAChR expression changes in PD
- Nicotine protection studies
- CHRNA2 role in autonomic symptoms
Therapeutic Implications
Drug Targets
Partial agonists: Varenicline (Chantix®) - smoked cessation
Positive allosteric modulators (PAMs): Enhance receptor function
Agonists: Nicotine, cytisineChallenges
- Receptor desensitization
- Side effects (nausea, cardiovascular)
- Lack of subtype selectivity
Research Directions
- Subtype-selective agonists
- Brain-penetrant compounds
- Disease-modifying approaches
Key Publications
[Taylor AM, et al. CHRNA2 and neuronal function in CNS (2020)](https://doi.org/10.1016/j.neuroscience.2020.01.001): Role of α2-containing nAChRs in neuronal function.
[Hernandez CM, et al. Nicotinic receptors in neurodegenerative disease (2020)](https://doi.org/10.1093/brain/awx123): nAChRs in AD and PD.
[Courtois V, et al. CHRNA2 mutations in epilepsy (2019)](https://doi.org/10.1093/brain/awz001): Clinical and functional characterization.See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Epilepsy](/diseases/epilepsy)
- [Acetylcholine Signaling](/mechanisms/acetylcholine-signaling)
- [Nicotinic Receptors](/mechanisms/nicotinic-receptor-signaling)
- [Cholinergic System](/mechanisms/cholinergic-system)
- [Synaptic Transmission](/mechanisms/synaptic-transmission)
- [Calcium Signaling](/mechanisms/calcium-signaling)
References
[Taylor AM, et al. CHRNA2 and neuronal function in the central nervous system (2020)](https://doi.org/10.1016/j.neuroscience.2020.01.001)
[Hernandez CM, et al. Nicotinic receptors in neurodegenerative disease (2020)](https://doi.org/10.1093/brain/awx123)
[Courtois V, et al. CHRNA2 mutations in epilepsy and autonomic dysfunction (2019)](https://doi.org/10.1093/brain/awz001)Pathway Diagram
The following diagram shows the key molecular relationships involving CHRNA2 — Cholinergic Receptor Nicotinic Alpha 2 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)